Sign In
Buy BAYRY
$13.89
-0.110 (-0.786%)
At Close: Jul 31, 2026
Bayer purchases heart drug for up to $310 mln
02:45am, Monday, 04'th Mar 2024
Bayer said on Monday it acquired the exclusive marketing rights for Europe for a new drug that is under regulatory review to treat a rare, potentially fatal heart disease for up to $310 million upfron
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe
02:33am, Monday, 04'th Mar 2024
BridgeBio Pharma has granted German drugmaker Bayer an exclusive license to commercialize its heart disease drug in Europe, the companies said on Monday.
Euro Stoxx 600 sits at ATH ahead of Bayer, Pirelli, Vivendi earnings
12:22am, Sunday, 03'rd Mar 2024
The Stoxx 600 index will be in the spotlight this week as the European Central Bank (ECB) delivers its second interest rate decision of the year. The index, which tracks the biggest European companies
Bayer not planning to announce split of company at Capital Markets Day - HB
08:24am, Friday, 01'st Mar 2024
Bayer is not planning to announce a split of its company at its Capital Markets Day next week, Handelsblatt said on Friday, citing people familiar with the matter.
Head of Bayer's consumer unit Schipper to be replaced by Julio Triana
11:18am, Thursday, 29'th Feb 2024
Bayer said that the head of its consumer health division, Heiko Schipper, would be replaced by Julio Triana, currently the unit's head of commercial operations region international.
Bayer investors weigh need for cash call amid stifling debt
05:01am, Thursday, 29'th Feb 2024
Bayer may have to ask shareholders for fresh capital to shore up its finances even after the debt-laden German drugmaker slashed dividends last week in its latest effort to get wiggle room, analysts s
Bayer slashes dividend by 95% as company faces wave of litigation over Roundup weed killer
12:35pm, Tuesday, 20'th Feb 2024
Bayer announced plans to cut its dividend a staggering 95% over the next three years as it looks to recover from debt associated with its acquisition of Monsanto Co., which thrust the German corporati
Bayer (BAYRY) Intends to Slash Dividends Amid Challenges
09:50am, Tuesday, 20'th Feb 2024
Bayer (BAYRY) announced plans to cut dividends to pay out only the legally required minimum for three years in the wake of high debt and increasing legal costs.
Moderna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut
02:34pm, Friday, 09'th Feb 2024
Shares of Metagenomi Technologies , a genetic medicines company backed by Bayer Healthcare and Moderna , slumped 32% in their Nasdaq debut on Friday.
US appeals court finds Bayer not shielded from Roundup lawsuits
02:40pm, Monday, 05'th Feb 2024
A U.S. appeals court on Monday refused to dismiss a lawsuit claiming that Bayer AG's Roundup weedkiller caused cancer, the latest setback in the company's efforts to fend off thousands of similar laws
Bayer to pay $2.25B after jury says Roundup weed killer gave man cancer
10:54am, Tuesday, 30'th Jan 2024
Bayer was ordered to pay $2.25 billion after a Pennsylvania jury unanimously ruled that its Roundup weed killer gave a man cancer.
Bayer faces Australian test with judge to decide whether weedkiller caused cancer
11:53pm, Monday, 29'th Jan 2024
An Australian court on Tuesday heard closing arguments in a class action lawsuit alleging that a weedkiller produced by Bayer caused cancer, the first such case in Australia to reach this stage.
Bayer shares slump after court tells firm to pay $2.25 billion over Monsanto weedkiller lawsuit
08:14am, Monday, 29'th Jan 2024
Shares in Bayer fell 5% on Monday after a Philadelphia jury told the German pharmaceutical company to pay $2.25 billion to a man who says he developed cancer due to using its Roundup branded weedkille
Bayer ordered to pay $2.25 billion in latest Roundup trial
05:07pm, Friday, 26'th Jan 2024
Bayer was ordered on Friday to pay $2.25 billion to a Pennsylvania man who said he developed cancer from exposure to the company's Roundup weedkiller, the man's attorneys said.
Bayer downgraded over 'multiple adverse factors' faced in 2024
08:55am, Wednesday, 10'th Jan 2024
Bayer AG (ETR:BAYN, OTC:BAYZF) will find it tough to hit last year's targets and faces multiple adverse factors in 2024, said Stifel as it downgraded the German pharma giant and cut its share price t
